Capital Analysts LLC Acquires 5,828 Shares of Becton, Dickinson and Company $BDX

Key Points

• Capital Analysts LLC increased its Becton, Dickinson and Company stake by 7.5% in the second quarter, purchasing 5,828 shares and bringing its holdings to 83,601 shares valued at approximately $12.65 million. Institutional investors collectively own 86.97% of BDX.
• Analyst sentiment is mixed, with eight Buy, eight Hold and one Sell rating; the consensus rating is Hold with a $187.67 price target. BDX recently traded at $179.35.
• BDX exceeded quarterly earnings and revenue estimates, reporting $3.23 in EPS and $4.98 billion in revenue, while revenue increased 5.4% year over year. The company declared a $1.05 quarterly dividend, equivalent to a 2.3% yield.

Capital Analysts LLC raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 7.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 83,601 shares of the medical instruments supplier's stock after buying an additional 5,828 shares during the period. Capital Analysts LLC's holdings in Becton, Dickinson and Company were worth $12,651,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in BDX. Imprint Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at approximately $25,000. SHP Wealth Management bought a new stake in Becton, Dickinson and Company during the fourth quarter worth approximately $26,000. Meeder Asset Management Inc. boosted its position in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier's stock worth $27,000 after purchasing an additional 102 shares during the period. Main Street Group LTD acquired a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc bought a new position in shares of Becton, Dickinson and Company in the second quarter valued at approximately $29,000. Institutional investors and hedge funds own 86.97% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on BDX shares. UBS Group assumed coverage on shares of Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a "buy" rating and a $190.00 price objective for the company. Weiss Ratings reiterated a "sell (d+)" rating on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Citigroup reissued a "buy" rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Wells Fargo & Company upped their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the company an "equal weight" rating in a report on Friday, August 7th. Finally, Bank of America lifted their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Monday, August 31st. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $187.67.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $179.35 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $193.07. The company has a fifty day moving average price of $171.21 and a 200 day moving average price of $160.61. The stock has a market cap of $49.42 billion, a P/E ratio of 54.02, a PEG ratio of 13.02 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same period last year, the business posted $3.68 EPS. The business's quarterly revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is currently 126.51%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael Garrison sold 1,100 shares of the company's stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 8,005 shares of company stock worth $1,423,580 over the last 90 days. Insiders own 0.40% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells medical devices, diagnostic products and laboratory equipment. Its offerings support healthcare providers, researchers, pharmaceutical manufacturers and patients across areas such as medication delivery, infection prevention, specimen collection, surgery and disease diagnosis.

BD's products include needles, syringes, catheters, infusion and medication-management systems, injection devices, blood-collection products, diagnostic testing platforms, laboratory automation equipment and flow cytometry systems.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.